6533b834fe1ef96bd129de60

RESEARCH PRODUCT

IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer

Stefan Rose-johnHans-anton LehrMassimo FantiniChristoph BeckerPeter R. GalleMarkus F. NeurathAlexei NikolaevStefan Wirtz

subject

Genetically modified mouseCell growthColorectal cancerCell BiologyBiologyEndoglinmedicine.diseaseTumor progressionIn vivoImmunologyCancer researchbiology.proteinmedicineADAM17 ProteinInterleukin 6Molecular BiologyDevelopmental Biology

description

Recent investigations support an important role for TGF-beta in the development of colorectal cancer. However, the molecular consequences of TGF-beta signaling in the colon remains incompletely understood. In a recent study in Immunity, we analyzed the role of TGF-beta in a murine model of colon cancer. Using transgenic mice overexpressing TGF-beta or a dominant negative TGF-beta receptor II under control of the CD2 minigene, we show that TGF-beta signaling in tumor infiltrating T lymphocytes regulates the growth of dysplastic colon epithelial cells, as determined by histology and a novel system for high resolution chromoendoscopy in vivo. At the molecular level, TGF-beta signaling in T cells regulated STAT-3 activation in tumor cells via IL-6. IL-6 signaling required tumor cell derived soluble IL-6R rather than membrane bound IL-6R and suppression of such TGF-beta-dependent IL-6 trans-signaling prevented tumor progression in vivo. Similar to these observations in mice, here we show that human colon cancer tissue expressed only low amounts of membrane bound IL-6R. In contrast, expression and activity of the matrix metalloproteinase TACE were increased. In summary, our data provide novel insights into the role of TGF-beta signaling in colorectal cancer and suggest novel therapeutic approaches for colorectal cancer based on an inhibition of TGF-beta-dependent IL-6 trans-signaling.

https://doi.org/10.4161/cc.4.2.1413